The company was founded in 2002, officially established in 2006, and listed on the main board of the Shanghai Stock Exchange in 2017. Weixinkang currently has 13 subsidiaries, distributed in Beijing, Tibet, Inner Mongolia, Hainan, Jiangsu, Hong Kong, and Singapore. The company is guided by clinical needs, based on R&D and innovation, and adhering to the combination of imitation. It is a comprehensive high-tech pharmaceutical enterprise integrating drug R&D, production and sales, and has significant advantages in the fields of intravenous vitamins, venous trace elements, and intravenous electrolytes. The company's main business is R&D, production and sales of chemical preparations and their raw materials. The company's leading products include injectable multivitamin (12), multi-microelement injection, pediatric multivitamin injection (13), compound electrolyte injection (V), etc. Corporate honors: Inner Mongolia Baiyi Pharmaceutical Master's Student Practice Base; Inner Mongolia Baiyi Pharmaceutical 2015 Trustworthy A-Class Enterprise; New Potassium Biomedical Product Certificate; Inner Mongolia Baiyi Pharmaceutical High-tech Enterprise; Inner Mongolia Baiyi Pharmaceutical Received the Honest Enterprise Certificate, etc.